Rein Therapeutics receives orphan drug designation for LTI-03 in idiopathic pulmonary fibrosis.

Rein Therapeutics has received orphan drug designation from the European Medicines Agency (EMA) for LTI-03, a drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products and recognizes the seriousness of IPF and the need for new treatment options. IPF is a rare, progressive lung disease characterized by irreversible scarring of lung tissue, leading to declining lung function and respiratory failure.